Every 8-K that Quest Diagnostics Inc (DGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics reported strong second-quarter 2026 results. Net revenues were $3.04 billion, up 10.2% year over year, including 10.0% organic revenue growth and a 13.1% increase in requisition volume, while revenue per requisition declined.
Reported diluted EPS rose 15.0% to $2.84, and adjusted diluted EPS increased 19.1% to $3.12. For the first six months of 2026, net revenues were $5,938 million and diluted EPS was $5.08. Operating cash flow reached $875 million, funding $252 million of capital expenditures and $100 million of share repurchases, as cash and equivalents increased to $626 million.
The company raised full‑year 2026 guidance, now expecting net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25. Expected cash from operations was increased to approximately $1.80 billion, with capital spending still projected at about $550 million.
Quest Diagnostics reported the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. All nominated directors were elected for terms expiring at the 2027 annual meeting, each receiving substantially more votes "for" than "against".
Stockholders approved the advisory resolution on executive officer compensation and ratified the appointment of PricewaterhouseCoopers as the company’s independent registered public accounting firm for 2026. A stockholder proposal requesting an independent board chairman did not receive sufficient support and was not approved.
Quest Diagnostics Incorporated entered into a material definitive agreement by issuing $500,000,000 aggregate principal amount of 5.000% senior notes due 2036. These notes are senior unsecured obligations that rank equally with the company’s other existing and future senior unsecured debt.
The notes mature on June 30, 2036, with interest paid at 5.000% on June 30 and December 30 each year, starting December 30, 2026. The indenture limits certain liens, sale-leaseback transactions, and major corporate restructurings, and requires Quest to offer to repurchase the notes at 101% of principal plus accrued interest upon a defined change of control triggering event.
Quest Diagnostics Incorporated has priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration statement. The company expects to receive net proceeds at closing on May 6, 2026, subject to customary conditions.
Quest plans to use the net proceeds for general corporate purposes, which may include repaying existing indebtedness, including its $500 million aggregate principal amount of 3.45% Senior Notes maturing on June 1, 2026. The company also entered into an underwriting agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC in connection with the offering.
Quest Diagnostics reported strong first quarter 2026 results and raised its full year 2026 outlook. Net revenues were $2.90 billion, up 9.2% from 2025, with Diagnostic Information Services revenues up 9.4%. Reported diluted EPS increased to $2.24, up 15.5%, while adjusted diluted EPS rose to $2.50, up 13.1%, reflecting improved profitability.
Operating income grew to $399 million, with adjusted operating margin edging up to 15.4% of net revenues. Cash provided by operations was $278 million, compared to $314 million a year earlier, while capital expenditures were $114 million. The company highlighted double-digit growth in Advanced Diagnostics and strong consumer-channel performance.
For full year 2026, Quest now expects net revenues of $11.78–$11.90 billion and reported diluted EPS of $9.58–$9.78. Adjusted diluted EPS is projected at $10.63–$10.83, above prior guidance, supported by solid first quarter execution and ongoing strategic initiatives.
Quest Diagnostics announced that its board of directors has elected Timothy (Tim) Wentworth, former chief executive officer of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, as a director. Including Mr. Wentworth, the board now has eleven members.
The board also appointed him to the Compensation and Leadership Development Committee and the Quality and Compliance Committee and determined he qualifies as an independent director under New York Stock Exchange standards and the company’s governance guidelines. As part of standard non-employee director compensation, he received a prorated one-time restricted share unit grant valued at approximately $43,000.
Quest highlights Mr. Wentworth’s extensive leadership background running large healthcare and consumer-focused organizations, including guiding Express Scripts into a Fortune 25 company with more than $100 billion in revenues before its acquisition by Cigna, as well as senior roles at Mary Kay and PepsiCo. The company’s press release with additional background is furnished as an exhibit.
Quest Diagnostics reported strong 2025 results with net revenues of $11.04 billion, up 11.8% from 2024, and reported diluted EPS of $8.75, up 13.8%. Adjusted diluted EPS was $9.85, up 10.3%. Fourth quarter revenue rose 7.1% to $2.81 billion, with diluted EPS of $2.18 and adjusted diluted EPS of $2.42. Cash from operations for 2025 was $1.89 billion.
The company issued 2026 guidance for net revenues of $11.70–$11.82 billion, reported diluted EPS of $9.45–$9.65, and adjusted diluted EPS of $10.50–$10.70. The Board raised the quarterly dividend 7.5% from $0.80 to $0.86 per share, or $3.44 annually, and expanded the share repurchase authorization by $1 billion, on top of approximately $0.4 billion remaining as of December 31, 2025.
Quest Diagnostics Incorporated is sharing an investor presentation about its strategy, business performance, and current market trends at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The slide deck used for this presentation is furnished as Exhibit 99.1 and contains the information discussed during the session.
The company notes that the materials may include forward-looking statements about its future results, which involve risks and uncertainties such as economic conditions, government investigations or lawsuits, competition, reimbursement complexity, regulatory changes, and acquisition activity. These risks are described in more detail in its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Quest Diagnostics (DGX) filed an 8‑K stating it issued a press release announcing its results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1, dated October 21, 2025.
The filing falls under Item 2.02 (Results of Operations and Financial Condition). Quest Diagnostics’ common stock trades on the NYSE under the symbol DGX.